A breakthrough antiviral compound has halted long COVID symptoms in mice, offering new hope for human treatments. Here’s what researchers discovered in 2025.
All posts by Oceanit
ASSURE In the News
Next-Gen COVID-19 Vaccines by INOVIO, Ocugen, Pfizer in 2025
Explore the latest COVID-19 vaccines in development by INOVIO, Ocugen, and Pfizer. Learn about new delivery platforms and what’s next in SARS-CoV-2 protection.
Why So Many Rapid COVID Tests Are Made in China?
Explore why Chinese companies dominate rapid COVID test manufacturing and which brands currently originate from China. Learn what this means for global health.
COVID-19 & Economy May Disrupt 2025 Summer Travel Season
Discover how COVID-19 variants and economic challenges may affect summer travel in 2025. Learn what precautions to take and how to stay healthy on the go.
Hawaii’s Innovation Legacy: From Past to ASSURE-100 COVID Test
Explore groundbreaking inventions from Hawaii’s history, including the ASSURE-100 Rapid COVID Test, developed locally during the global pandemic.
Why Rapid COVID Tests Are Underused & Why You Still Need Them
Despite ongoing COVID-19 risk, rapid tests remain underused in 2025. Learn why you should keep them in your medicine cabinet and how they help stop spread.
How 2025 Economic Turmoil May Affect COVID-19 Worldwide
U.S. economic turmoil and shifting federal policies in 2025 may threaten COVID-19 funding, surveillance, and vaccine access. Learn what’s at stake at home and abroad.
Latest 2025 COVID-19 Vaccine Guidance by Age Group in the U.S.
Explore updated 2025 vaccine guidance for older Americans, adults, and children. Learn who needs boosters and how to stay protected against SARS-CoV-2.
Judge Blocks HHS’ $11B COVID Grant Clawback to States
A federal judge halts the HHS attempt to claw back $11B in COVID-19 grants. Learn how this impacts state health programs and pandemic preparedness funding.
Anti-Vaccine Sentiment Threatens Future FDA Vaccine Approvals
Concerns rise as anti-vaccine views in government threaten the approval process for new vaccines awaiting FDA and regulatory review in 2025.